Pyoderma gangrenosum induced by secukinumab in a patient with psoriasis successfully treated with ustekinumab
Amy J. Petty, Melodi Javid Whitley, Alexandra Balaban, Kenneth S. Ellington, Anne L. Marano
Abstract
Pyoderma gangrenosum is an inflammatory condition characterized by the presence of painful and necrotic ulcerations with a neutrophil-rich infiltrate. Although its pathogenesis is not completely understood, pyoderma gangrenosum has been associated with autoimmune disorders, such as inflammatory bowel disease. Drug-induced pyoderma gangrenosum has also been reported in the literature, particularly in relation to new targeted therapies including infliximab, adalimumab, and rituximab.1 Herein, we present a novel case of pyoderma gangrenosum induced by secukinumab, an anti-interleukin (IL) 17A antibody in a patient with psoriasis.
Topics & Concepts
Pyoderma gangrenosumSecukinumabMedicineUstekinumabInflammatory bowel diseasePsoriasisDermatologyInfliximabAdalimumabInterleukin 23AnakinraRituximabImmunologyInterleukinDiseaseAntibodyTumor necrosis factor alphaCytokinePathologyPsoriatic arthritisAutoimmune and Inflammatory DisordersHidradenitis Suppurativa and TreatmentsOral Health Pathology and Treatment